{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:08:16Z","timestamp":1778760496763,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06437-7","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:17:00Z","timestamp":1778757420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemotherapy-induced anemia as a prognostic factor for overall survival in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy and cystectomy"],"prefix":"10.1007","volume":"44","author":[{"given":"Elsa","family":"Lafitte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Sfumato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Walz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilien","family":"Billon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Branger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Vicier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Rybikowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Maubon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Beaufils","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lor\u00e8ne","family":"Seguin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naji","family":"Salem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Brunelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9raldine","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwenaelle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"1","key":"6437_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes J, Max Bruins H, Carri\u00f3n A, Cathomas R, Comp\u00e9rat E, Efstathiou JA et al (2024) European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur Urol 85(1):17\u201331","journal-title":"Eur Urol"},{"key":"6437_CR2","doi-asserted-by":"publisher","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y et al (2021) Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med [Internet]. Jun 2 [cited 2023 Nov 14]; Available from: https:\/\/www.nejm.org\/doi\/https:\/\/doi.org\/10.1056\/NEJMoa2034442","DOI":"10.1056\/NEJMoa2034442"},{"issue":"2","key":"6437_CR3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","volume":"65","author":"F Petrelli","year":"2014","unstructured":"Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S (2014) Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol 65(2):350\u2013357","journal-title":"Eur Urol"},{"issue":"6","key":"6437_CR4","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.3390\/cancers15061742","volume":"15","author":"S Culine","year":"2023","unstructured":"Culine S, Harter V, Krucker C, Gravis G, Fl\u00e9chon A, Chevreau C et al (2023) Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Cancers 15(6):1742","journal-title":"Cancers"},{"issue":"18","key":"6437_CR5","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.21.02051","volume":"40","author":"C Pfister","year":"2022","unstructured":"Pfister C, Gravis G, Fl\u00e9chon A, Chevreau C, Mahammedi H, Laguerre B et al (2022) Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. J Clin Oncol Off J Am Soc Clin Oncol 40(18):2013\u20132022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"6437_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.euo.2018.09.004","volume":"2","author":"L Boeri","year":"2019","unstructured":"Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M et al (2019) Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes. Eur Urol Oncol 2(4):390\u2013396","journal-title":"Eur Urol Oncol"},{"issue":"15","key":"6437_CR7","first-page":"2293","volume":"40","author":"H Ludwig","year":"2004","unstructured":"Ludwig H, Van Belle S, Barrett-Lee P, Birgeg\u00e5rd G, Bokemeyer C, Gasc\u00f3n P et al (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer Oxf Engl 1990 40(15):2293\u20132306","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"6437_CR8","doi-asserted-by":"crossref","unstructured":"Munting KE, Klein AA (2019) Optimisation of pre-operative anaemia in patients before elective major surgery - why, who, when and how? Anaesthesia. 74(Suppl 1):49\u201357","DOI":"10.1111\/anae.14466"},{"issue":"4","key":"6437_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1053\/ctrv.2000.0181","volume":"26","author":"S Mercadante","year":"2000","unstructured":"Mercadante S, Gebbia V, Marrazzo A, Filosto S (2000) Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev 26(4):303\u2013311","journal-title":"Cancer Treat Rev"},{"key":"6437_CR10","doi-asserted-by":"crossref","unstructured":"Carvalho FLF, Wang Y, Dall CP, Nayan M, Chou WH, McGregor B et al (2022) Preoperative anemia is associated with increased radical cystectomy complications. Urol Oncol. ;40(8):382.e7-382.e13","DOI":"10.1016\/j.urolonc.2022.04.014"},{"issue":"11","key":"6437_CR11","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/bjs.9861","volume":"102","author":"AJ Fowler","year":"2015","unstructured":"Fowler AJ, Ahmad T, Phull MK, Allard S, Gillies MA, Pearse RM (2015) Meta-analysis of the association between preoperative anaemia and mortality after surgery. Br J Surg 102(11):1314\u20131324","journal-title":"Br J Surg"},{"key":"6437_CR12","first-page":"3528","volume":"23","author":"C Chen","year":"2017","unstructured":"Chen C, Hu L, Li X, Hou J (2017) Preoperative Anemia as a Simple Prognostic Factor in Patients with Urinary Bladder Cancer. Med Sci Monit Int Med J Exp Clin Res 23:3528\u20133535","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"issue":"10","key":"6437_CR13","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s00432-015-1957-7","volume":"141","author":"M Gierth","year":"2015","unstructured":"Gierth M, Mayr R, Aziz A, Krieger S, Wullich B, Pycha A et al (2015) Preoperative anemia is associated with adverse outcome in patients with urothelial carcinoma of the bladder following radical cystectomy. J Cancer Res Clin Oncol 141(10):1819\u20131826","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"6437_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11255-016-1219-x","volume":"48","author":"JK Jo","year":"2016","unstructured":"Jo JK, Jeong SJ, Hong SK, Byun SS, Lee SE, Oh JJ (2016) The impact of preoperative anemia on oncologic outcome in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Int Urol Nephrol 48(4):489\u2013494","journal-title":"Int Urol Nephrol"},{"key":"6437_CR15","doi-asserted-by":"crossref","unstructured":"Moschini M, Bianchi M, Rossi MS, Dell\u05f3Oglio P, Gandaglia G, Fossati N et al (2016) Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. Urol Oncol. ;34(6):256.e7-256.e13","DOI":"10.1016\/j.urolonc.2015.12.016"},{"issue":"6","key":"6437_CR16","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.eururo.2014.08.051","volume":"66","author":"EJ Abel","year":"2014","unstructured":"Abel EJ, Linder BJ, Bauman TM, Bauer RM, Thompson RH, Thapa P et al (2014) Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? Eur Urol 66(6):1139\u20131147","journal-title":"Eur Urol"},{"key":"6437_CR17","doi-asserted-by":"publisher","first-page":"101592","DOI":"10.1016\/j.suronc.2021.101592","volume":"38","author":"D Uysal","year":"2021","unstructured":"Uysal D, Egen L, Grilli M, Wessels F, Lenhart M, Michel MS et al (2021) Impact of perioperative blood transfusions on oncologic outcomes after radical cystectomy: A systematic review and meta-analysis of comparative studies. Surg Oncol 38:101592","journal-title":"Surg Oncol"},{"issue":"5","key":"6437_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.mpaic.2009.01.017","volume":"10","author":"S Hellings","year":"2009","unstructured":"Hellings S, Blajchman MA (2009) Transfusion-related immunosuppression. Anaesth Intensive Care Med 10(5):231\u2013234","journal-title":"Anaesth Intensive Care Med"},{"issue":"1","key":"6437_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/21681805.2020.1716067","volume":"54","author":"R Rosenblatt","year":"2020","unstructured":"Rosenblatt R, Lorentzi G, Bahar M, Asad D, Forsman R, Johansson M et al (2020) Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival. Scand J Urol 54(1):46\u201351","journal-title":"Scand J Urol"},{"issue":"12","key":"6437_CR20","doi-asserted-by":"publisher","first-page":"102741","DOI":"10.1016\/j.fjurol.2024.102741","volume":"34","author":"M Roumigui\u00e9","year":"2024","unstructured":"Roumigui\u00e9 M, Marcq G, Neuzillet Y, Bajeot AS, Allory Y, Sargos P et al (2024) French AFU Cancer Committee Guidelines \u2013 Update 2024\u20132026: Muscle-invasive bladder cancer (MIBC). Fr J Urol 34(12):102741","journal-title":"Fr J Urol"},{"issue":"12S","key":"6437_CR21","first-page":"S78","volume":"30","author":"M Roupr\u00eat","year":"2020","unstructured":"Roupr\u00eat M, Pignot G, Masson-Lecomte A, Comp\u00e9rat E, Audenet F, Roumigui\u00e9 M et al (2020) [French ccAFU guidelines - update 2020\u20132022: bladder cancer]. Progres En Urol J Assoc Francaise Urol Soc Francaise Urol 30(12S):S78\u2013135","journal-title":"Progres En Urol J Assoc Francaise Urol Soc Francaise Urol"},{"issue":"8","key":"6437_CR22","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.21037\/tau-22-78","volume":"11","author":"V Eriksson","year":"2022","unstructured":"Eriksson V, Holmlund J, Wiberg E, Johansson M, Huge Y, Alamdari F et al (2022) Adverse events during neoadjuvant chemotherapy for muscle invasive bladder cancer-a Swedish retrospective multicentre study of a clinical database. Transl Androl Urol 11(8):1105\u20131115","journal-title":"Transl Androl Urol"},{"issue":"1","key":"6437_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.euf.2015.03.002","volume":"2","author":"M Moschini","year":"2016","unstructured":"Moschini M, Bianchi M, Gandaglia G, Cucchiara V, Luzzago S, Pellucchi F et al (2016) The Impact of Perioperative Blood Transfusion on Survival of Bladder Cancer Patients Submitted to Radical Cystectomy: Role of Anemia Status. Eur Urol Focus 2(1):86\u201391","journal-title":"Eur Urol Focus"},{"issue":"6","key":"6437_CR24","first-page":"739","volume":"57","author":"AI Ceanga","year":"2018","unstructured":"Ceanga AI, Ceanga M, Eveslage M, Herrmann E, Fischer D, Haferkamp A et al (2018) Preoperative anemia and extensive transfusion during stay-in-hospital are critical for patient`s mortality: A retrospective multicenter cohort study of oncological patients undergoing radical cystectomy. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis 57(6):739\u2013745","journal-title":"Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis"},{"issue":"1","key":"6437_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/bju.14012","volume":"121","author":"MW Vetterlein","year":"2018","unstructured":"Vetterlein MW, Gild P, Kluth LA, Seisen T, Gierth M, Fritsche HM et al (2018) Peri-operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score-weighted European multicentre study. BJU Int 121(1):101\u2013110","journal-title":"BJU Int"},{"key":"6437_CR26","doi-asserted-by":"publisher","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","volume":"92","author":"S Hussaini","year":"2021","unstructured":"Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S et al (2021) Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis. Cancer Treat Rev 92:102134","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"6437_CR27","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1001\/jamaoncol.2021.0732","volume":"7","author":"J Naidoo","year":"2021","unstructured":"Naidoo J, Zhang J, Shankar B (2021) Immune-Related Adverse Events and Efficacy-The More It Hurts, the Better It Works?-Reply. JAMA Oncol 7(6):945","journal-title":"JAMA Oncol"},{"issue":"11","key":"6437_CR28","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1093\/annonc\/mdu444","volume":"25","author":"MV Abola","year":"2014","unstructured":"Abola MV, Prasad V, Jena AB (2014) Association between treatment toxicity and outcomes in oncology clinical trials. Ann Oncol 25(11):2284\u20132289","journal-title":"Ann Oncol"},{"issue":"7","key":"6437_CR29","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/sj.bjc.6602783","volume":"93","author":"B Schuell","year":"2005","unstructured":"Schuell B, Gruenberger T, Kornek GV, Dworan N, Depisch D, Lang F et al (2005) Side effects during chemotherapy predict tumour response in advanced colorectal cancer. Br J Cancer 93(7):744\u2013748","journal-title":"Br J Cancer"},{"issue":"3","key":"6437_CR30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/bjc.2011.256","volume":"105","author":"CK Lee","year":"2011","unstructured":"Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G et al (2011) Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Br J Cancer 105(3):360\u2013365","journal-title":"Br J Cancer"},{"issue":"2","key":"6437_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/bjc.1997.49","volume":"75","author":"T Saarto","year":"1997","unstructured":"Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75(2):301\u2013305","journal-title":"Br J Cancer"},{"issue":"1","key":"6437_CR32","first-page":"487","volume":"19","author":"Y Ishibashi","year":"2020","unstructured":"Ishibashi Y, Tsujimoto H, Hiraki S, Kouzu K, Tsuchiya S, Itazaki Y et al (2020) Predictive value of immuno-inflammatory and nutritional measures modulated by neoadjuvant chemotherapy on the response of neoadjuvant chemotherapy and long-term outcomes in patients with esophageal cancer. Oncol Lett 19(1):487\u2013497","journal-title":"Oncol Lett"},{"issue":"7","key":"6437_CR33","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1158\/1078-0432.CCR-07-2068","volume":"14","author":"P Dubsky","year":"2008","unstructured":"Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M et al (2008) Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide\/methotrexate\/5-fluorouracil chemotherapy. Clin Cancer Res Off J Am Assoc Cancer Res 14(7):2082\u20132087","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"6437_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.tracli.2004.11.005","volume":"12","author":"P Vaupel","year":"2005","unstructured":"Vaupel P, Mayer A (2005) Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus Clin Biol J Soc Francaise Transfus Sang 12(1):5\u201310","journal-title":"Transfus Clin Biol J Soc Francaise Transfus Sang"},{"issue":"3","key":"6437_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.semradonc.2004.04.007","volume":"14","author":"C Leo","year":"2004","unstructured":"Leo C, Giaccia AJ, Denko NC (2004) The hypoxic tumor microenvironment and gene expression. Semin Radiat Oncol 14(3):207\u2013214","journal-title":"Semin Radiat Oncol"},{"issue":"9392","key":"6437_CR36","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","volume":"362","author":"M Henke","year":"2003","unstructured":"Henke M, Laszig R, R\u00fcbe C, Sch\u00e4fer U, Haase KD, Schilcher B et al (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet Lond Engl 362(9392):1255\u20131260","journal-title":"Lancet Lond Engl"},{"issue":"9674","key":"6437_CR37","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/S0140-6736(09)60502-X","volume":"373","author":"J Bohlius","year":"2009","unstructured":"Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J et al (2009) Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet Lond Engl 373(9674):1532\u20131542","journal-title":"Lancet Lond Engl"},{"issue":"24","key":"6437_CR38","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1056\/NEJMp078101","volume":"356","author":"FR Khuri","year":"2007","unstructured":"Khuri FR (2007) Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 356(24):2445\u20132448","journal-title":"N Engl J Med"},{"issue":"14","key":"6437_CR39","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.3390\/jcm11144156","volume":"11","author":"S Buchrits","year":"2022","unstructured":"Buchrits S, Itzhaki O, Avni T, Raanani P, Gafter-Gvili A (2022) Intravenous Iron Supplementation for the Treatment of Chemotherapy-Induced Anemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med 11(14):4156","journal-title":"J Clin Med"},{"issue":"6","key":"6437_CR40","first-page":"CD012633","volume":"6","author":"A Adams","year":"2022","unstructured":"Adams A, Scheckel B, Habsaoui A, Haque M, Kuhr K, Monsef I et al (2022) Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis. Cochrane Database Syst Rev 6(6):CD012633","journal-title":"Cochrane Database Syst Rev"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06437-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06437-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06437-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:17:06Z","timestamp":1778757426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06437-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6437"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06437-7","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This retrospective observational monocentric study was conducted in accordance with the Declaration of Helsinki. According to French regulations, patients were informed about the study and, in the absence of any expressed objection, were included.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"364"}}